Genome-wide association study of prostate cancer-specific survival.
Szulkin R., Karlsson R., Whitington T., Aly M., Gronberg H., Eeles RA., Easton DF., Kote-Jarai Z., Al Olama AA., Benlloch S., Muir K., Giles GG., Southey MC., FitzGerald LM., Henderson BE., Schumacher FR., Haiman CA., Sipeky C., Tammela TLJ., Nordestgaard BG., Key TJ., Travis RC., Neal DE., Donovan JL., Hamdy FC., Pharoah PDP., Pashayan N., Khaw K-T., Stanford JL., Thibodeau SN., McDonnell SK., Schaid DJ., Maier C., Vogel W., Luedeke M., Herkommer K., Kibel AS., Cybulski C., Lubiński J., Kluźniak W., Cannon-Albright L., Brenner H., Herrmann V., Holleczek B., Park JY., Sellers TA., Lim H-Y., Slavov C., Kaneva RP., Mitev VI., Spurdle A., Teixeira MR., Paulo P., Maia S., Pandha H., Michael A., Kierzek A., PRACTICAL consortium None., Batra J., Batra J., Clements JA., Australian Prostate Cancer BioResource None., Albanes D., Andriole GL., Berndt SI., Chanock S., Gapstur SM., Giovannucci EL., Hunter DJ., Kraft P., Le Marchand L., Ma J., Mondul AM., Penney KL., Stampfer MJ., Stevens VL., Weinstein SJ., Trichopoulou A., Bueno-de-Mesquita BH., Tjønneland A., Cox DG., BPC3 consortium None., Maehle L., Schleutker J., Lindström S., Wiklund F.
Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).We observed no significant association between genetic variants and prostate cancer survival.Common genetic variants with large impact on prostate cancer survival were not observed in this study.Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.